Long‐term outcomes of high‐dose (74 GyE) proton beam therapy with concurrent chemotherapy for stage III nonsmall‐cell lung cancer. Issue 9 (6th March 2021)

• Record Type: Journal Article
• Authors: Ohnishi, Kayoko; Ishikawa, Hitoshi; Nakazawa, Kensuke; Shiozawa, Toshihiro; Mori, Yutaro; Nakamura, Masatoshi; Okumura, Toshiyuki; Sekine, Ikuo; Hizawa, Nobuyuki; Sakurai, Hideyuki
• Is Part Of: Thoracic cancer. Volume 12:Issue 9(2021)
• Page Start: 1320
• Page End: 1327
• Publication Date: 2021-03-06
• Subjects: concurrent chemotherapy -- proton beam therapy -- stage III non‐small cell lung cancer; Chest -- Cancer -- Periodicals; Chest -- Cancer -- Treatment -- Periodicals; Chest -- Surgery -- Periodicals; 616.99494005
• DOI: 10.1111/1759-7714.13896
• Languages: English
• ISSNs: 1759-7706

Abstract

Abstract: Background: To evaluate the long‐term outcomes of high‐dose (74 GyE) proton beam therapy (PBT) with concurrent chemotherapy for stage III non‐small cell lung cancer (NSCLC). Methods: Between July 2007 and March 2018, 45 patients with stage III NSCLC were treated with passive‐scattering PBT of 74 GyE and concurrent chemotherapy. Among the 45 patients, the median age was 62 years (range 39–79 years) and 32 patients were men. The clinical stages were stage IIIA in 14 patients and stage IIIB in 31 patients. Thirty‐six patients received chemotherapy consisting of cisplatin and vinorelbine. Results: The median follow‐up time was 42.1 months (range 6.4–127.0 months) for all patients and 63.5 months (range 9.4–127.0 months) for the 12 survivors. The 3‐ and 5‐year overall survival rates were 63.7% and 38.8%, respectively, and the median overall survival was 49.1 months. Over the follow‐up period, disease recurrence was observed in 32 (71%) patients. The 3‐ and 5‐year progression‐free survival rates were 22.2% and 17.7%, respectively, with a median progression‐free survival of 13.1 months. In‐field control improved survival and the in‐field control rate was better in patients with T0–3 tumors ( p = 0.023) and stage IIIA/IIIB‐N3 disease ( p = 0.030). Dosimetric parameters of the heart and lung were not associated with survival. No grade 4 or 5 acute or late non‐hematologic toxicities were observed. Conclusions: Passive‐scattering PBT of 74 GyE with chemotherapy showed favorable survival and a low incidence of severe adverse events in patients with stage III NSCLC. Abstract : Forty‐five patients with stage III non‐small cell lung cancer (14 stage IIIA, 31 stage IIIB) who received high‐dose (74 GyE) passive‐scattering proton beam therapy (PBT) with concurrent chemotherapy were retrospectively reviewed to analyze survivals and toxicities. The 3‐ and 5‐year overall survival rates were 63.7% and 38.8%, respectively, and the median overall survival was 49.1 months. Passive‐scattering PBT of 74 GyE with chemotherapy showed favorable survival and a low incidence of severe adverse events in patients with stage III NSCLC.